The combined use of two molecules makes it possible to treat metastatic prostate cancer more effectively in patients with genetic abnormalities that affect their ability to repair their DNA, demonstrates an international study in which a researcher from the Centre participated.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
The combined use of two molecules makes it possible to treat metastatic prostate cancer more effectively in patients with genetic abnormalities that affect their ability to repair their DNA, demonstrates an international study in which a researcher from the Centre participated.